United States: The New Patent Policy on Natural Products Is a Game Changer for Universities and Life Sciences Companies

Last Updated: September 24 2014
Article by Nicholas J. Landau, Ph.D

Since the 19th Century, it has been considered a given that a person who identifies and purifies a useful natural substance is entitled to a patent, so long as the substance had never before existed in pure form. Due to a new policy enacted by the U.S. Patent and Trademark Office (USPTO), this has recently changed, with serious effects on companies and universities that conduct research in the life sciences. In the view of the USPTO, such inventions can no longer be patented because of the Supreme Court's decision in Association for Molecular Pathology v. Myriad Genetics, 569 U.S. 12 (2013). On March 4th of this year, the USPTO issued lengthy guidelines ("the Guidance") to their patent examiners, instructing them to reject any patent claim to a purified natural product.1 From all accounts the examiners have taken this guidance to heart and have been rejecting a wide range of life sciences inventions as a result.

This article explains the contents of the Guidance, their practical effects on the patenting of life science inventions, and possible ways life sciences companies and universities can mitigate their negative impacts.

What Was the Status Quo Ante?

Prior to the Myriad decision, purified natural substances could be patented. The Myriad decision held that isolated DNA that has exactly the same sequence as is found in nature cannot be patented. This created doubt as to whether other purified natural substances had lost their patent-eligible status.

An early example of a patent for a purified natural substance is U.S. Patent 141,072 issued to Louis Pasteur in 1873, which claimed beer yeast "free from organic germs of disease." Likewise, Jokichi Takamine was the first to purify adrenaline, for which he was granted U.S. Patent No. 730,176. Felix Hoffman received U.S. Patent 644,077 in 1898 for purified acetyl salicylic acid, the active ingredient in aspirin.2 Perhaps the best example of a patent for a purified natural substance is Selman Waksman's U.S. Patent 2,449,866 for the landmark antibiotic streptomycin. Waksman's claim 13 reads, in its entirety, "Streptomycin."

Countless additional examples exist. These are some of the most valuable products of the revolution in biology sparked by the discovery in the 19th Century that organisms are composed of chemicals. They include a large fraction of modern drugs and other useful materials.

What Inventions Are Affected?

The Guidance states that it applies to all "natural products" or combinations of natural products. That categorization by itself is unhelpful, as all possible inventions must contain one or more natural products (for example, an aluminum can contains aluminum, a naturally occurring element). The Guidance provides some clarification by providing the following non-exclusive list of materials that fall under the new rules:

  1. Chemicals derived from natural sources (including antibiotics, fats, oils, petroleum derivatives, resins, toxins, etc.)
  2. Foods
  3. Metals and metallic compounds that exist in nature
  4. Minerals
  5. Natural materials (rocks and soil)
  6. Nucleic acids
  7. Organisms (including bacteria, plants, and multicellular animals)
  8. Proteins and peptides
  9. Other substances found in or derived from nature

It should be noted that some categories of materials are limited to those "found in nature" or that "exist in nature," and others are limited to those "derived" from nature. However, others, such as minerals, organisms, nucleic acids, peptides, and proteins, contain no such limitations, and are apparently subject to the new rules regardless of whether they are found in nature or derived from natural sources.

Which Inventions Can Be Patented?

Any invention that involves some "natural product" (including but not limited to those listed above) must comply with new requirements in order to be eligible for patenting. This applies to any invention that includes a natural product as one of its parts, or that uses a natural product in some type of process. It also applies to inventions that do not involve any natural product, but instead involve something that is not "significantly different" from a natural product.

The Guidance proposes a set of 12 factors that must be considered by a patent examiner in determining whether any invention that involves a natural product is eligible for patenting. The goal of the Guidance is to help a patent examiner determine whether a patent claim is "significantly different" from a product of nature. Unfortunately, the subjective nature of the factors and the large number of factors prevent straightforward and predictable analysis.3

More helpful are the five examples of common types of patent claims for natural products given in the Guidance;4 in each of the five examples the Guidance provides a conclusion as to whether the invention is eligible for patenting. These examples are summarized below.

Plasmids are analyzed in Example A. In that example, the Guidance states that a plasmid that is defined only by its function, if that function exists in natural plasmids, cannot be patented. The Guidance also considers whether a bacterium containing two plasmids defined by their functions can be patented. The Guidance concludes that such a bacterium could be patented, so long as natural bacteria do not contain two such plasmids, and the plasmids confer a function that is not found in natural bacteria. The implication of this example is that, if a change to the structure of a naturally occurring thing (such as a bacterium) results in a change in function, this is a significant enough difference to allow it to be patented.

Phytochemicals are considered in Example B. In that example, the Guidance states that a purified form of a natural phytochemical cannot be patented, even if the phytochemical is useful when purified and nearly useless in its natural state. This example states that a modified (methylated) form of a phytochemical can be patented in cases in which the modified form has a function that the natural form does not. The example finally states that a process of treating a disease with the natural phytochemical may be patented, if limited to a specific dosage regimen. The Guidance does not address whether the treatment method could be patented absent the specific dosage regimen. This last question is significant, as it is rare that a working dosage regimen will have been established for a new drug by the time a patent application has been filed.

Examples A and B imply that a change to the structure of a naturally occurring thing resulting in a change in function is a sufficient difference to allow it to be patented.

Fireworks are oddly included in Example C, which does not seem relevant to the life sciences. However, this example states that "gunpowder as recited in the claim [is] not markedly different from what exists in nature." The clear implication is that the USPTO views gunpowder – a mix of various substances made in several ways that never existed prior to its creation by human hands – as a "natural product" that cannot be patented. Merely by including gunpowder in the invention, the "natural product" analysis must be performed. In light of such reasoning, it is difficult to imagine an invention that does not involve a "product of nature" in the eyes of the USPTO, regardless of whether in the final analysis the invention can be patented.

Microbial consortia are the subject of Example D. In this example, a microbial consortium cannot be patented, when all of the species in the consortium are natural, and each species has the same function in the consortium as it does alone. Although the example acknowledges that such a consortium has a wider range of uses than would a single species, it states that because "no species acquires a different use" the consortium is not significantly different from the species in isolation from one another.

In this example, despite a difference in both structure and function between the invention and what is natural, the Guidance concludes that the invention cannot be patented. This example could stand for the proposition that a combination of natural things, in which the function of the whole is no more than the sum of its parts, is not "significantly different" from the things alone. Although the "structure" of the consortium is new, because the species had never lived in consortium in nature, there was no new function as a result.

Polymerase chain reaction (PCR) primers are the subject of Example E, specifically when a pair of primers contains only natural sequences (as is true when primers flank natural genes). The example concludes that a claim for the pair of PCR primers cannot be patented. Both of the primers are isolated versions of naturally occurring sequences, and absent any additional structures or components to distinguish the primers from what occurs naturally, the Guidance finds that the two primers in combination are no more patentable than either would be alone.

In contrast, the Guidance concludes that the process of using the primers in PCR can be patented, for the reason that the specific steps required by PCR (denaturing, polymerizing, renaturing, and providing the proper reagents) limit the use of the primers to a specific artificial application.

This last example is extremely helpful, as it clearly explains that at least one aspect of this common type of biotechnological invention can be patented.

What Should Life Sciences Inventors Do?

Despite the wide-ranging implications of the Guidance, patent applicants should not necessarily forgo attempts to protect their purified natural products or combinations of natural products for the following reasons.

The Guidance May Be Invalidated

The Guidance does not have the force of law. Patent examiners will follow the Guidance, but courts and higher administrative authorities (such as the Patent Trial and Appeals Board, which reviews the examiners' decisions) are not bound by them. The Guidance is a significant departure from the law as it was previously understood and is a significant departure from international standards of patenting. Inevitably it will be challenged in a court of law. The Guidance has received considerable criticism from legal commentators, and it is quite possible that it will be invalidated, in whole or in part, upon such challenge. Consequently, patent applicants should consider maintaining the ability to claim subject matter that might be rejected under the Guidance, in case such a challenge should succeed.

Pay Attention to Foreign Markets

Countries outside of the United States have not shown any interest in following the lead of the USPTO in creating this new exception to patenting. The U.S. and most industrialized countries have signed the Trade-Related Aspects of Intellectual Property Rights (TRIPS) agreement, which allows its participants to exempt only specific types of subject matter from patenting. "Natural products" are not one of the permitted exemptions.5 Although the United States remains the world's largest market in terms of nominal GDP, the European Union (EU) as a whole exceeds the GDP of the U.S. Taken together, the EU, China, and Japan have a GDP that is slightly less than twice that of the United States. Even if the Guidance survives judicial challenges, these foreign markets remain quite lucrative and permit purified natural substances and combinations of natural substances to be patented, so inventors should consider retaining the ability to claim these types of inventions in foreign patents. Based on the increased patenting risk in the U.S., life sciences innovators may also wish to consider shifting the focus of their research to problems that are consequential in major markets outside of the U.S., and away from problems that are unique to the U.S. or primarily of consequence in the U.S.

Consider Trade Secrecy

Patents are not the only form of intellectual property protection available. Certain types of inventions can be protected as trade secrets, and as the U.S. weakens its patent laws, trade secrecy is becoming a more popular form of IP protection. The balance between secrecy and patenting has always been a consideration for innovators in every area of technology, but the Guidance is yet another nudge in the direction of secrecy for life sciences inventions.

For drugs, biologics, and medical devices, trade secrecy is generally impractical, because of the need to obtain regulatory approval from the U.S. Food and Drug Administration.6 For inventions subject to the Guidance that do not require regulatory approval, an analysis should be conducted to determine whether the invention should be maintained as a trade secret.

Before publishing or presenting newly identified genes or other useful natural substances, serious consideration should be given to maintaining any newly discovered natural substance in strict secrecy until its commercial potential can be ascertained, so that patent applications can be filed for all commercially viable, artificially modified forms. In addition, if the substance could be useful in an industry outside of those which have mandated rules of public disclosure, then consideration should be given to maintaining the invention as a permanent trade secret.

Footnotes

[1] The Guidance discusses to a lesser extent inventions that involve "natural principles," but that topic is not within the scope of this article.

[2] Although acetyl salicylic acid is not naturally occurring, it had been made in impure form before Hoffman purified it.

[3] As examples of the subjective nature of the factors, Factor (c) requires a determination of whether the public is "substantially foreclosed from using" the natural product. Factor (g) requires the patent examiner to determine whether elements of the invention are "markedly different in structure." Terms such as "substantially" and "markedly" are intentionally vague, and would be interpreted differently by different people.

[4] The Guidance contains three examples of "laws of nature," which are not discussed here.

[5] TRIPS allows participants to declare that inventions cannot be patented for diagnostic methods, therapeutic methods, surgical methods, plants, animals (but not microorganisms), essentially biological processes for the production of plants or animals, and anything that threatens public order, public morality, human health, animal health, plant health, or the environment. Note that the Guidance specifically states that microorganisms are "natural products," but that TRIPS specifically states that microorganisms are not exempt from patenting.

[6] This is also true to some extent for food additives, cosmetics, dietary supplements, and pesticides, although not in all circumstances.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
In association with
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.

Disclaimer

Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.

Registration

Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.

Cookies

A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.

Links

This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.

Mail-A-Friend

If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.

Emails

From time to time Mondaq may send you emails promoting Mondaq services including new services. You may opt out of receiving such emails by clicking below.

*** If you do not wish to receive any future announcements of services offered by Mondaq you may opt out by clicking here .

Security

This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.